Patients Discontinuing Slimming Jabs Gain Back Pounds Four Times Faster Than People Using Diet and Exercise

Fresh analysis suggests that people who stop using blockbuster slimming jabs like semaglutide or tirzepatide can put back on reduced body mass far faster than those who halt traditional diet and exercise regimens.

Research printed in a major medical journal points out that while overweight individuals often shed about a fifth of their body weight while using the jabs, the weight returns at an estimated rate of nearly a kilo each month after stopping.

"Individuals using such drugs should be aware of the risk of quick weight regain when the therapy concludes," cautioned researcher Dr. Susan Jebb.

Such speed of recovery means a reversion to pre-treatment mass within about a year and a half.

Comparing Approaches

The research, which examined 37 of studies involving over 9,000 of patients, compared the outcomes of GLP-1 agonists with other pills.

The team point out that individuals who lose weight through lifestyle changes alone generally experience a slower weight regain—approximately 0.1 kg a month—post-intervention.

Understanding the Rapid Rebound

Doctors suggest the mode of action of the drugs accounts for the amplified rebound.

GLP-1 drugs imitate a natural hormone called glucagon-like peptide-1, which controls feelings of fullness.

"Artificially providing GLP-1 concentrations far above than the body's typical production may cause the system to produce less of its endogenous GLP-1, and could reduce responsiveness to its effects," noted Dr. Adam Collins, a nutrition specialist.

"Withdrawal of this medication results in hunger is no longer kept in check, making excessive eating much more probable."

A Chronic Issue?

Medical guidelines advise the jabs for individuals with obesity-related health risks, accompanied by recommended diet and exercise modifications.

A number of clinicians say that, given the high risk of weight regain, the therapy is often life-long.

This view is echoed by drug manufacturers, who say that the findings "underscore the persistent character of obesity," akin to managing conditions like high blood pressure.

Patient Testimonies

Users who have discontinued the medication explain a intense resurgence of hunger.

"It felt as if something that goes on and you're instantly starving," described a patient.

This difficulty is compounded if individuals have not established sustainable dietary or behavioural changes during therapy.

Growing Interest

Survey data indicate that millions of people in the UK have tried these injections in the last 12 months, with desire being substantial.

• Use is greater among women than males.
• The 40s and 50s demographic shows the greatest level of interest.
• A large proportion access the medications through private prescriptions rather than public health services.

In conclusion, clinicians caution that while these medications are powerful agents for shedding pounds, they are not a permanent fix and maintained weight loss hinges on integrated lifestyle changes.